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Marilia Harumi Higuchi dos Santos, MD, PhD;* Abhinav Sharma, MD;* Jie-Lena Sun, MS; Karen Pieper, MS; John J.V. McMurray, MB, ChB, MD;
Rury R. Holman, FRCP, FMedSci; Renato D. Lopes, MD, PhD, MHS
Background-—Regional differences in risk of diabetes mellitus and cardiovascular outcomes in people with impaired glucose
tolerance are poorly characterized. Our objective was to evaluate regional variation in risk of new-onset diabetes mellitus,
cardiovascular outcomes, and treatment effects in participants from the NAVIGATOR (Nateglinide and Valsartan in Impaired
Glucose Tolerance Outcomes Research) trial.
Methods and Results-—NAVIGATOR randomized people with impaired glucose tolerance and cardiovascular risk factors or with
established cardiovascular disease to valsartan (or placebo) and to nateglinide (or placebo) with a median 5-year follow-up. Data
from the 9306 participants were categorized by 5 regions: Asia (n=552); Europe (n=4909); Latin America (n=1406); North America
(n=2146); and Australia, New Zealand, and South Africa (n=293). Analyzed outcomes included new-onset diabetes mellitus;
cardiovascular death; a composite cardiovascular outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal
stroke; and treatment effects of valsartan and nateglinide. Respective unadjusted 5-year risks for new-onset diabetes mellitus,
cardiovascular death, and the composite cardiovascular outcome were 33%, 0.4%, and 4% for Asia; 34%, 2%, and 6% for Europe;
37%, 4%, and 8% for Latin America; 38%, 2%, and 6% for North America; and 32%, 4%, and 8% for Australia, New Zealand, and South
Africa. After adjustment, compared with North America, European participants had a lower risk of new-onset diabetes mellitus
(hazard ratio 0.86, 95% CI 0.78–0.94; P=0.001), whereas Latin American participants had a higher risk of cardiovascular death
(hazard ratio 2.68, 95% CI 1.82–3.96; P<0.0001) and the composite cardiovascular outcome (hazard ratio 1.48, 95% CI 1.15–1.92;
P=0.003). No differential interactions between treatment and geographic location were identified.
Conclusions-—Major regional differences regarding the risk of new-onset diabetes mellitus and cardiovascular outcomes in
NAVIGATOR participants were identified. These differences should be taken into account when planning global trials.
Clinical Trial Registration-—URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00097786. ( J Am Heart Assoc. 2017;6:
e003892. DOI: 10.1161/JAHA.116.003892.)
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T he prevalence of diabetes mellitus is increasing globally,especially in low-income countries.1 The global preva-
lence of patients with impaired fasting glucose or impaired
glucose tolerance (IGT) is also rapidly increasing. It is
projected that >470 million adults globally will develop
impaired fasting glucose or IGT by 2030.1,2 People with IGT
have an increased risk of developing type 2 diabetes mellitus
and cardiovascular disease.3,4 Interventions that might reduce
the conversion from IGT to diabetes mellitus and reduce the
associated rates of death and complications from cardiovas-
cular causes are highly desirable. Several trials have shown
that lifestyle modification5 and pharmacological therapy,
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including metformin,6 acarbose,7 and rosiglitazone,8 reduce
the incidence of diabetes mellitus. Examination of regional
registries suggests differences in the conversion from IGT to
diabetes mellitus,9–11 yet variable methodology, length of
follow-up, and differences in collected data limit comparisons
between regions. Furthermore, it is unclear whether interna-
tional geographic location influences the risk of cardiovascu-
lar outcomes or response to treatments in people with IGT.
The NAVIGATOR (Nateglinide and Valsartan in Impaired
Glucose Tolerance Outcomes Research) trial assessed
whether nateglinide, a short-acting insulin secretagogue, or
valsartan, an angiotensin receptor blocker, could reduce the
risk of new-onset diabetes mellitus and/or cardiovascular
events among people with IGT and established cardiovascular
disease or cardiovascular risk factors.12,13 The NAVIGATOR
trial recruited from 40 countries, providing an opportunity to
evaluate the potential role of regional differences in out-
comes. Using NAVIGATOR data, we aimed to assess the
association between international geographic location and the
risk of new-onset diabetes mellitus, cardiovascular death, a
composite cardiovascular outcome, and treatment effects of
valsartan and nateglinide.
Methods
Study Population and Trial Design
The study design, participant characteristics, and outcomes of
the NAVIGATOR study have been published.12–14 Briefly,
NAVIGATOR was a prospective multicenter randomized con-
trolled trial with a 292 factorial design that included 9306
patients with IGT and established cardiovascular disease or
cardiovascular risk factors. Participants were assigned ran-
domly to receive valsartan (up to 160 mg daily) or placebo
and, simultaneously, nateglinide (up to 60 mg 3 times daily)
or placebo, in addition to lifestyle modification. Men and
women with IGT and ≥1 cardiovascular risk factor (aged
≥55 years) or with known cardiovascular disease (aged
≥50 years) were eligible for participation in NAVIGATOR.
Exclusion criteria included laboratory abnormalities or condi-
tions that could interfere with assessment of the safety or
efficacy of a study drug, the use of an angiotensin-converting
enzyme inhibitor (ACEI) or angiotensin receptor blocker for
the treatment of hypertension, and the use of an antidiabetic
medication within the previous 5 years. Participants were
followed prospectively for a median of 5 years for the
occurrence of 3 coprimary outcomes: (1) new-onset diabetes
mellitus; (2) a core cardiovascular outcome that was a
composite of death from cardiovascular causes, nonfatal
myocardial infarction, nonfatal stroke, or hospitalization for
heart failure; and (3) an extended cardiovascular outcome that
was a composite of the individual components of the core
composite outcome plus either hospitalization for unstable
angina or arterial revascularization. Deaths, hospitalizations,
and potential cardiovascular events that did not result in
hospitalization were adjudicated by an independent commit-
tee whose members were unaware of the treatment assign-
ments. Valsartan (but not nateglinide) reduced the incidence
of diabetes mellitus by 14%. Neither valsartan nor nateglinide
reduced the risk of the other coprimary end points. The
NAVIGATOR trial was approved by the appropriate institu-
tional review boards, and all participants provided written
informed consent.
For this study, data from all 9306 NAVIGATOR trial
participants were analyzed and divided into the following 5
regions: Asia; Europe; Latin America; North America; and
Australia, New Zealand, and South Africa (AU/NZ/SAf). Four
major outcomes based on international geographic location
were evaluated: (1) development of diabetes mellitus; (2)
cardiovascular death; (3) a composite cardiovascular outcome
of cardiovascular mortality, nonfatal myocardial infarction, or
nonfatal stroke; and (4) differential treatment response to
valsartan or nateglinide.
Statistical Analysis
Continuous baseline variables were summarized as medians
with 25th and 75th percentiles, and categorical factors and
the number of participants with a characteristic per region
were summarized as percentages. Between-group compar-
isons of continuous measures were performed using Kruskal–
Wallis tests. Categorical factors were compared using Pear-
son chi-square or Fisher exact tests. The event rates at
5 years by region were summarized using Kaplan–Meier rates
and compared using log-rank tests.
Multivariable Cox proportional hazards regression models
were developed previously to determine factors associated
with NAVIGATOR outcomes.15 Region was included as a
covariate in these models, with North America as the
reference group. For the development of diabetes mellitus,
adjustments were made for age; sex; body mass index (in
kg/m2); systolic blood pressure; family history of diabetes
mellitus; the composite of history of myocardial infarction,
unstable angina, coronary revascularization, stroke, or heart
failure; fasting glucose; 2-hour glucose on oral glucose
tolerance testing; hemoglobin A1c; low-density lipoprotein
cholesterol; high-density lipoprotein cholesterol; platelet
count; and hemoglobin concentration. Cardiovascular death
risk was adjusted for age; sex; renal dysfunction; the
composite of history of myocardial infarction, unstable angina,
or coronary revascularization; current smoking; ECG; ECG
interpretation; the composite of stroke, transient ischemic
attack, or history of cerebrovascular disease; log urinary
albumin:creatinine ratio; peripheral arterial disease; history of
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heart failure; hemoglobin concentration; chronic obstructive
pulmonary disease; atrial fibrillation; and estimated glomeru-
lar filtration rate. The composite cardiovascular outcome was
adjusted for age; sex; race; the composite of history of
myocardial infarction, unstable angina, or coronary revascu-
larization; current smoking; ECG interpretation; the composite
of stroke, transient ischemic attack, or history of cerebrovas-
cular disease; log urinary albumin:creatinine ratio; history of
pulmonary embolism or deep vein thrombosis; low-density
lipoprotein cholesterol; peripheral arterial disease; history of
heart failure; hemoglobin concentration; chronic obstructive
pulmonary disease; pulse pressure; waist circumference; atrial
fibrillation; serum sodium; and estimated glomerular filtration
rate. To adjust for country-specific measures of wealth and
poverty, we conducted a sensitivity analysis adjusting for
gross domestic product as a continuous variable in addition to
the variables mentioned previously. We conducted an addi-
tional secondary analysis after excluding patients with
baseline ACEI use to remove those with potentially dual ACEI
and angiotensin receptor blocker treatment (351 patients at
baseline and 460 patients at the end of 4 years). Single
imputation was implemented by creating a monotone missing
pattern using the Markov chain Monte Carlo method and then
by completing each data set by regression models for
monotone missing. The proportional hazards assumption
was tested by plotting the Schoenfeld residuals by time and
then testing for a nonzero slope; there were no violations, so
we reported the single hazard ratio (HR) as an average over
time. Because this was a hypothesis-generating analysis, we
did not make any adjustments for multiple hypothesis testing.
Possible regional differences in treatment effects for
valsartan versus placebo and for nateglinide versus placebo
were evaluated, with potential interactions between treatment
and region tested for each outcome in adjusted Cox
proportional hazards regression models. Missing data were
handled by single imputation. SAS 8.3–9.3 (SAS Institute,
Cary, NC) was used for all analyses.
Results
Baseline characteristics by region for the 9306 NAVIGATOR
participants are shown in Table 1. In total, 4909 (53%)
patients were enrolled from Europe, 2146 (23%) from North
America, 1406 (15%) from Latin America, 552 (6%) from Asia,
and 293 (3%) from AU/NZ/SAf. The distributions of partic-
ipants recruited per country are provided in Table 2.
Baseline Demographics and Medical History
Latin America had the highest proportion of female partici-
pants (59.6%), whereas AU/NZ/SAf had the lowest (47.8%).
Europe had the highest proportion of current smokers
(12.7%), and Asia had the lowest (7.2%). North America had
the highest proportion of black participants (8.5%), and Asia
had the lowest (0.0%). Participants in Europe also had the
highest systolic (141 mm Hg) and diastolic (84 mm Hg)
blood pressures. Participants in North America had the
highest body mass index (31.5 kg/m2), the largest waist
circumference (104 cm), and the most frequent family history
of diabetes mellitus (51.9%). AU/NZ/SAf had the highest rate
of baseline cardiovascular disease (composite of myocardial
infarction, unstable angina, coronary revascularization, history
of stroke, and history of heart failure) at 34.5%, followed by
Europe at 34.3%. Latin America had the lowest rate of
baseline cardiovascular disease (25.2%). Participants from
Asia had the lowest body mass index (25.8) and systolic blood
pressure (131 mm Hg).
Medication Use and Laboratory Findings
Lipid-lowering medication and aspirin use was highest in
North America (54.5% and 46.8%, respectively) and lowest in
Asia (24.5% and 25.9%, respectively). ACEI use was highest in
AU/NZ/SAf (9.9%), followed by North America (9.3%). Beta
blocker and diuretic use was highest in Latin America (42.7%
and 36.0%, respectively). Calcium channel blocker use was
highest in Asia (46.9%). Europe had the highest low-density
lipoprotein cholesterol (3.4 mmol/L) and total cholesterol
(5.5 mmol/L), whereas North America had the lowest
(2.8 and 5.0 mmol/L, respectively). Europe had the highest
high-density lipoprotein cholesterol (1.28 mmol/L), whereas
Asia had the lowest (1.11 mmol/L). Latin America had the
highest triglyceride levels (1.9 mmol/L) and the highest
estimated glomerular filtration rate (82.1 mL/min per
1.73 m2). Fasting glucose was highest in Latin America and
Europe (both 6.1 mmol/L). Hemoglobin A1c appeared to be
uniform across regions (5.8%), although it was numerically
higher in AU/NZ/SAf (6%).
Outcomes
New-onset diabetes mellitus
The incidence and risk of new-onset diabetes mellitus at
5 years varied significantly among the 5 regions (Tables 3 and
4). North America had the highest unadjusted rate (38%),
whereas AU/NZ/SAf had the lowest (32%). In the multivari-
able Cox model, risk of new-onset diabetes mellitus was lower
in Europe (HR 0.86, 95% CI 0.78–0.94; P=0.001) and AU/NZ/
SAf (HR 0.75, 95% CI 0.61–0.93; P=0.009) compared with
North America (Figure 1, Table 5). The results were similar in
the sensitivity analysis, which included adjustment for gross
domestic product (HR 0.79, 95% CI 0.67–0.92; P=0.003)
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(Table 6). Furthermore, the removal of patients with ACEI use
did not significantly alter the results (HR 0.88, 95% CI 0.79–
0.97; P=0.009) (Table 7).
Cardiovascular death and the composite cardiovascular
outcome
The unadjusted incidence of cardiovascular death at 5 years
differed significantly among the regions studied (Table 3).
Latin America had the highest incidence at 3.6%, whereas
Asia had the lowest at 0.4%. AU/NZ/SAf had the highest rate
of the composite cardiovascular outcome at 7.9%, followed by
Latin America at 7.6%. In the adjusted model (Figure 2,
Table 5), risk of cardiovascular death was higher in Latin
America (HR 2.68, 95% CI 1.82–3.96; P<0.0001) and AU/NZ/
SAf (HR 2.32, 95% CI 1.22–4.40; P=0.01) compared with
North America (Figure 3). In the adjusted model for the
composite cardiovascular outcome, compared with North
America, only Latin America continued to demonstrate an
increased risk (HR 1.48, 95% CI 1.15–1.92, P=0.003). Using
the sensitivity analysis after adjustment for gross domestic
product, a similar magnitude of risk was seen in Latin America
in both the composite outcome (HR 1.51, 95% CI 0.93–2.44;
P=0.09) and cardiovascular death (HR 2.84, 95% CI 1.21–
6.67; P=0.02) (Table 6). Results were similar after excluding
patients who were on an ACEI at baseline (Table 7).
Differential Treatment Effect Among Regions for
Valsartan and Nateglinide
There were no significant interactions for valsartan or
nateglinide with region with respect to new-onset diabetes
mellitus (P=0.11 and P=0.80, respectively), cardiovascular
death (P=0.94 and P=0.07, respectively), or the composite
cardiovascular outcome (P=0.99 and P=0.48, respectively).
Discussion
In this study, compared with North America, Europe and AU/
NZ/SAf had lower risks of new-onset diabetes mellitus,
whereas Latin America had higher risks of cardiovascular
Table 2. Enrollment by Country
Characteristic Total=9306
Asia 552 (5.93%)
China (mainland) 301 (3.23%)
Hong Kong 65 (0.70%)
Malaysia 51 (0.55%)
Singapore 9 (0.10%)
Taiwan 126 (1.35%)
Europe 4909 (52.75%)
Austria 71 (0.76%)
Belgium 45 (0.48%)
Czech Republic 60 (0.64%)
Denmark 239 (2.57%)
Finland 247 (2.65%)
France 114 (1.23%)
Germany 137 (1.47%)
Greece 22 (0.24%)
Hungary 215 (2.31%)
Italy 668 (7.18%)
Netherlands 205 (2.20%)
Norway 37 (0.40%)
Poland 339 (3.64%)
Russia 634 (6.81%)
Slovakia 66 (0.71%)
Spain 124 (1.33%)
Sweden 94 (1.01%)
Switzerland 30 (0.32%)
Turkey 76 (0.82%)
United Kingdom 1486 (15.97%)
Latin America 1406 (15.11%)
Argentina 720 (7.74%)
Brazil 328 (3.52%)
Chile 30 (0.32%)
Colombia 85 (0.91%)
Ecuador 24 (0.26%)
Guatemala 52 (0.56%)
Mexico 100 (1.07%)
Peru 52 (0.56%)
Uruguay 15 (0.16%)
North America 2146 (23.06%)
Canada 340 (3.65%)
United States (including Puerto Rico) 1806 (19.41%)
Continued
Table 2. Continued
Characteristic Total=9306
Other 293 (3.15%)
Australia 107 (1.15%)
New Zealand 33 (0.35%)
South Africa 153 (1.64%)
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death and the composite cardiovascular outcome after
multivariable adjustment. No regional differences in treatment
effects for valsartan or nateglinide were identified.
Differences in Clinical Trial Participants
Global clinical trials are increasingly used to reduce costs, to
enroll participants rapidly, to ensure timely completion, to
provide global applicability, and to satisfy regulatory require-
ments. Potential problems, however, include regional differ-
ences in patient characteristics, medical practice patterns,
and health care policies that may influence outcomes and
ultimately limit generalizability.16 As seen in our study,
despite stringent inclusion and exclusion criteria, baseline
characteristics demonstrated significant variation by region.
Such variation has been seen previously in cardiovascular
trials ranging from heart failure to atrial fibrillation.16 Potential
reasons for these variations in baseline characteristics include
differences in study trial conduct, interpretation of inclusion
and exclusion criteria, ascertainment of outcomes, differences
in the demographics of patients available to be recruited, and
investigator preferences in recruiting patients.
Even within geographic regions, there is likely significant
heterogeneity by country. In our study, Europe had the highest
low-density lipoprotein cholesterol and total cholesterol levels
compared with other geographic regions. Countries such as
Russia, Poland, Slovakia, and Hungary have some of the
highest out-of-pocket health expenditures, rank low on the
World Health Organization health system performance index,
and have the highest total cholesterol levels globally.17 In our
study, 1254 patients were enrolled from these countries
(25.5% of all patients enrolled in Europe). In comparison, the
United Kingdom, Finland, and Denmark have some of the
lowest out-of-pocket health expenditures, have higher World
Health Organization health system performance index met-
rics, and have some of the lowest total cholesterol levels
globally.17 Such regional differences in participant demo-
graphics reflect the need for careful selection of countries to
participate in cardiovascular clinical trials, as differences in
baseline clinical characteristics and therapies may influence
trial results.
International Variation in Progression to Diabetes
Mellitus
Externally validated risk-prediction models use factors such as
age, sex, ethnicity, body mass index, waist circumference,
family history of diabetes mellitus, systolic blood pressure,
Table 3. Unadjusted 5-Year Event Rate Based on Outcome and Region
Region
Development of
Diabetes Mellitus, % Cardiovascular Death
Composite of Cardiovascular
Death, MI, and Stroke
% (95% CI)
Asia (n=552) 33 (29–38) 0.36 (0.09–1.44) 4.04 (2.68–6.07)
Europe (n=4909) 34 (32–35) 1.67 (1.34–2.08) 5.53 (4.91–6.23)
Latin America (n=1406) 37 (35–40) 3.63 (2.75–4.77) 7.61 (6.32–9.16)
North America (n=2146) 38 (36–40) 1.93 (1.42–2.64) 5.90 (4.93–7.05)
Australia, New Zealand, and South Africa (n=293) 32 (26–38) 3.58 (1.94–6.54) 7.94 (5.3–11.81)
Log-rank* <0.001 <0.001 0.02
MI indicates myocardial infarction.
*Log-rank compares incidence among the regions.
Table 4. Unadjusted HRs for the Development of Outcomes Based on Regions
Country
Development of Diabetes
Mellitus Cardiovascular Death
Composite of Cardiovascular
Death, MI, and Stroke
HR (95% CI); P Value
Asia vs North America 0.76 (0.65–0.89); <0.001 0.47 (0.21–1.04); 0.06 0.71 (0.48–1.06); 0.09
Europe vs North America 0.84 (0.78–0.92); <0.001 0.90 (0.64–1.25); 0.52 0.94 (0.77–1.15); 0.56
Latin America vs North America 0.93 (0.84–1.04); 0.21 1.89 (1.31–2.72); <0.001 1.24 (0.97–1.57); 0.08
Australia, New Zealand, South Africa
vs North America
0.80 (0.64–0.98); 0.03 1.73 (0.92–3.24); 0.09 1.27 (0.83–1.94); 0.28
HR indicates hazard ratio; MI, myocardial infarction.
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and high-density lipoprotein cholesterol, among other factors,
to predict the risk of developing diabetes mellitus.18 Despite
the prespecified inclusion and exclusion criteria, the signifi-
cant variability in the baseline characteristics of patients
enrolled based on geographic region combined with unmea-
sured and unrecognized social, physical activity participation,
health care delivery, and genetic factors likely contributes to
the different risks of diabetes mellitus that we described.
Compared with North America, the risk of diabetes mellitus
development appears to be lowest in European patients. As
seen in our study, a higher prevalence of risk factors such as
obesity, waist circumference, and family history of diabetes
mellitus in North America compared with Europe11 may be a
major driver of this increased risk of conversion from the
prediabetic state to full diabetes mellitus.11,19 In addition,
lower numbers of higher-risk minority groups, such as black
patients in the European region (0.3%) compared with the
North America region (8.5%), may also contribute significantly
to the lower risk of progression to diabetes mellitus.19
International Variation in NAVIGATOR Trial
Outcomes
International variation in clinical trial outcomes are likely due
to a complex interplay of patient baseline characteristics (eg,
race, genetics, nutritional status, education, and medication
adherence), regional medical culture, and processes of care.16
Developing regions, such as Latin America, are experiencing a
growing burden of cardiovascular disease20 and related risk
factors such as type 2 diabetes mellitus.21 These findings may
result from deficits in preventive strategies, genetic factors,
exposure to Western countries’ high-fat diets, and increasing
prevalence of sedentary behaviors.21 The PURE (Prospective
Urban and Rural Epidemiological) study, which enrolled
156 424 persons across 17 countries, identified that
although the burden of cardiovascular risk factors may be
lower in low- to middle-income countries, the risk of
cardiovascular events was much higher.20 This may reflect
superior control of risk factors and more frequent use of
proven pharmacological therapies and revascularization in
high-income countries.20 Differences in cardiovascular out-
comes based on regions have been shown in patients with
diabetes mellitus.22 Our findings support this concept, as
patients in Latin America used fewer therapies for prevention
of cardiovascular events, such as aspirin (32% versus 47% in
North America and 35% in Europe), lipid-lowering therapies
Table 5. Adjusted HRs for the Development of Outcomes Based on Regions
Country
Development of Diabetes
Mellitus* Cardiovascular Death†
Composite of Cardiovascular
Death, MI, and Stroke‡
HR (95% CI); P Value
Asia vs North America 0.93 (0.79–1.10); 0.41 0.66 (0.30–1.47); 0.31 0.90 (0.59–1.37); 0.63
Europe vs North America 0.86 (0.78–0.94); 0.001 1.05 (0.74–1.48); 0.80 0.92 (0.74–1.14); 0.44
Latin America vs North America 0.95 (0.85–1.06); 0.37 2.68 (1.82–3.96); <0.0001 1.48 (1.15–1.92); 0.003
Australia, New Zealand, South Africa
vs North America
0.75 (0.61–0.93); 0.009 2.32 (1.22–4.40); 0.01 1.40 (0.91–2.15); 0.13
HR indicates hazard ratio; MI, myocardial infarction.
*Adjusted for age sex; body mass index; systolic blood pressure; family history of diabetes mellitus; the composite of history of MI, unstable angina, coronary revascularization, stroke, or
heart failure; fasting glucose; 2-hour glucose on oral glucose tolerance test; hemoglobin A1c; low-density lipoprotein cholesterol; high-density lipoprotein cholesterol; platelet count; and
hemoglobin concentration.
†Adjusted for age; sex; renal dysfunction; the composite of history of MI, unstable angina, or coronary revascularization; current smoking; ECG interpretation; the composite of stroke,
transient ischemic attack, or history of cardiovascular disease; log urinary albumin:creatinine ratio; peripheral arterial disease; history of heart failure; hemoglobin concentration; chronic
obstructive pulmonary disease; atrial fibrillation; and estimated glomerular filtration rate.
‡Adjusted for age; sex; race; the composite of history of MI, unstable angina, or coronary revascularization; current smoking; ECG interpretation; the composite of stroke, transient
ischemic attack, or history of cardiovascular disease; log urinary albumin:creatinine ratio; history of pulmonary embolism or deep vein thrombosis; low-density lipoprotein cholesterol;
peripheral arterial disease; history of heart failure; hemoglobin concentration; chronic obstructive pulmonary disease; pulse pressure; waist circumference; atrial fibrillation; serum sodium;
and estimated glomerular filtration rate.
Figure 1. Adjusted event curves for incidence of diabetes
mellitus by region. Other indicates Australia, New Zealand, and
South Africa.
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(28% versus 55% in North America and 35% in Europe), and
ACEIs (4% versus 9% in North America and 8% in Europe).
These variations in outcomes have significant implications for
future global clinical trials because regions will have to be
selected carefully based on expected event rates.
Therapeutic Treatment Effect Based on
Geographic Location
This analysis suggests that there were no regional differences
in treatment effects for valsartan or nateglinide. Our results
suggest that the impact of valsartan in reducing progression
to diabetes mellitus—despite the differences in baseline
therapies, background drug treatment, patient characteristics,
and risk of outcomes—is independent of geographic region.
This has important implications for hypertension management
in regions such as Latin America, which has a high risk of
conversion from prediabetes to diabetes mellitus. NAVIGATOR
data show that antihypertensive use is highest in Latin
America and that use of beta blockers and thiazide diuretics is
common. These drugs can increase risk of progression to
diabetes mellitus,23 and so angiotensin receptor blocker
agents could be considered as preferred antihypertension
management for people with IGT in Latin America.
Table 7. Sensitivity Analysis After Removing Patients With Baseline Angiotensin-Converting Enzyme Inhibitor for the Development
of Outcomes Based on Regions
Country
Development of Diabetes
Mellitus* Cardiovascular Death†
Composite of Cardiovascular
Death, MI, and Stroke‡
HR (95% CI); P Value
Asia vs North America 0.93 (0.78–1.11); 0.42 0.52 (0.22–1.24); 0.14 0.85 (0.55–1.31); 0.46
Europe vs North America 0.88 (0.79–0.97); 0.009 0.97 (0.66–1.42); 0.86 0.88 (0.69–1.11); 0.28
Latin America vs North America 0.95 (0.84–1.06); 0.35 2.27 (1.48–3.49); 0.0002 1.36 (1.03–1.80); 0.03
Australia, New Zealand, South Africa
vs North America
0.73 (0.58–0.92); 0.007 2.01 (0.97–4.17); 0.06 1.16 (0.70–1.91); 0.56
HR indicates hazard ratio; MI, myocardial infarction.
*Adjusted for age sex; body mass index; systolic blood pressure; family history of diabetes mellitus; the composite of history of MI, unstable angina, coronary revascularization, stroke, or
heart failure; fasting glucose; 2-hour glucose on oral glucose tolerance test; hemoglobin A1c; low-density lipoprotein cholesterol; high-density lipoprotein cholesterol; platelet count; and
hemoglobin concentration.
†Adjusted for age; sex; renal dysfunction; the composite of history of MI, unstable angina, or coronary revascularization; current smoking; ECG interpretation; the composite of stroke,
transient ischemic attack, or history of CV disease; log urinary albumin:creatinine ratio; peripheral arterial disease; history of heart failure; hemoglobin concentration; chronic obstructive
pulmonary disease; atrial fibrillation; and estimated glomerular filtration rate.
‡Adjusted for age; sex; race; the composite of history of MI, unstable angina, or coronary revascularization; current smoking; ECG interpretation; the composite of stroke, transient
ischemic attack, or history of CV disease; log urinary albumin:creatinine ratio; history of pulmonary embolism or deep vein thrombosis; low-density lipoprotein cholesterol; peripheral
arterial disease; history of heart failure; hemoglobin concentration; chronic obstructive pulmonary disease; pulse pressure; waist circumference; atrial fibrillation; serum sodium; and
estimated glomerular filtration rate.
Table 6. Sensitivity Analysis With Multivariable Adjustment Including Gross Domestic Product for the Development of Outcomes
Based on Regions
Country
Development of Diabetes
Mellitus* Cardiovascular Death†
Composite of Cardiovascular
Death, MI, and Stroke‡
HR (95% CI); P Value
Asia vs North America 0.85 (0.69–1.06); 0.15 0.70 (0.24–2.04); 0.51 0.92 (0.52–1.61); 0.76
Europe vs North America 0.79 (0.67–0.92); 0.003 1.11 (0.51–2.41); 0.80 0.93 (0.61–1.44); 0.75
Latin America vs North America 0.86 (0.72–1.04); 0.11 2.84 (1.21–6.67); 0.02 1.51 (0.93–2.45); 0.09
Australia, New Zealand, South Africa
vs North America
0.68 (0.53–0.88); 0.004 2.46 (0.92–6.62); 0.07 1.42 (0.79–2.58); 0.24
HR indicates hazard ratio; MI, myocardial infarction.
*Adjusted for age sex; body mass index; systolic blood pressure; family history of diabetes mellitus; the composite of history of MI, unstable angina, coronary revascularization, stroke, or
heart failure; fasting glucose; 2-hour glucose on oral glucose tolerance test; hemoglobin A1c; low-density lipoprotein cholesterol; high-density lipoprotein cholesterol; platelet count; and
hemoglobin concentration.
†Adjusted for age; sex; renal dysfunction; the composite of history of MI, unstable angina, or coronary revascularization; current smoking; ECG interpretation; the composite of stroke,
transient ischemic attack, or history of CV disease; log urinary albumin:creatinine ratio; peripheral arterial disease; history of heart failure; hemoglobin concentration; chronic obstructive
pulmonary disease; atrial fibrillation; and estimated glomerular filtration rate.
‡Adjusted for age; sex; race; the composite of history of MI, unstable angina, or coronary revascularization; current smoking; ECG interpretation; the composite of stroke, transient
ischemic attack, or history of CV disease; log urinary albumin:creatinine ratio; history of pulmonary embolism or deep vein thrombosis; low-density lipoprotein cholesterol; peripheral
arterial disease; history of heart failure; hemoglobin concentration; chronic obstructive pulmonary disease; pulse pressure; waist circumference; atrial fibrillation; serum sodium; and
estimated glomerular filtration rate.
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Study Limitations
Our study has some limitations. Because these data were
collected in the context of a clinical trial, with prespecified
inclusion and exclusion criteria, they may not accurately
reflect the regions’ real-world populations. In addition, these
are post hoc analyses and are subject to the limitations of
such analyses. Despite statistical adjustments, unmeasured
confounders may still be present. With the available data, we
were only able to adjust for current history of smoking and
not cumulative smoking history. Detailed demographic infor-
mation regarding race (beyond white, black, Asian, and
others) was unavailable. A causal relationship between
geographic region and outcomes cannot be determined.
Furthermore, there is likely significant variation among
practice pattern, health care delivery, and participant charac-
teristics, even within a given region. Our analysis focuses on
baseline characteristics and does not account for changes in
risk factors or background drug treatment throughout the
duration of the trial. In addition, the AU/NZ/SAf region
reflects a geographically heterogeneous population with small
numbers of patients and events, and hence any interpretation
of risk in this group should be viewed with caution. However,
the strength of our analysis arises from several factors: (1) the
NAVIGATOR study is one of the largest trials in patients with
IGT and cardiovascular risk factors; (2) the event rate allows
for comprehensive multivariable adjustment; and (3) the well-
phenotyped patients in this clinical trial provide the ability to
adjust for important clinical, demographic, and biochemical
variables. Furthermore, our sensitivity analysis, which
adjusted for gross domestic product (a country’s measure
of wealth and poverty), verified our key findings that the risk
of progression to diabetes mellitus was lowest in Europe and
the risk of cardiovascular death was highest in Latin America.
In addition, removing patients with baseline ACEI use did not
change results.
Conclusion
Our analysis of the NAVIGATOR trial demonstrated that
geographic regions significantly influence the risk of diabetes
mellitus and cardiovascular outcomes in patients with IGT.
Important differences in baseline risk factors among regions
existed. Differences in the risk of development of diabetes
mellitus and adverse cardiovascular events based on geo-
graphic region must be considered when conducting interna-
tional trials in patients with IGT. The use of angiotensin
receptor blocker agents as antihypertensive therapy in
patients with IGT could be considered in regions with high
risk of progression to diabetes mellitus. Future studies to
identify causal factors contributing to the differential risk of
diabetes mellitus progression and cardiovascular outcomes
based on geographic region are needed.
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